
TWYMEEG® sales continued to increase in Japan for the last quarter 2024 (October-December) by 17% over the prior quarter and by 154% over Q4 2023 TWYMEEG®’s FY 20241 revised forecast2 of JPY 7.9...
Regulatory News: POXEL SA (Euronext : POXEL - FR0012432516), société biopharmaceutique au stade clinique développant des traitements innovants pour les maladies chroniques graves à...
Poxel announces that a Combined General Meeting will be held on February 11, 2025, at 9:00 a.m. CET and the availability of the preparatory documents Poxel announces the addition of a new...
Durée de vie des brevets couvrant l’Imeglimine en Chine étendue jusqu’en 2039 Poursuite des discussions en vue d’un partenariat pour le développement et la commercialisation de l’Imeglimine en...
Poxel eligible for royalties equaling 10% of all TWYMEEG® net sales for 20241 and a one-time sales-based payment of JPY 500 million (EUR 3.1 million2) Allocation of all revenues received to the...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.022 | -7.45762711864 | 0.295 | 0.3075 | 0.25 | 370138 | 0.27633483 | DE |
4 | 0.0908 | 49.8353457739 | 0.1822 | 0.3985 | 0.163 | 1081223 | 0.30007089 | DE |
12 | 0.028 | 11.4285714286 | 0.245 | 0.3985 | 0.115 | 717799 | 0.24469502 | DE |
26 | -0.356 | -56.5977742448 | 0.629 | 0.747 | 0.115 | 474817 | 0.32633607 | DE |
52 | -0.275 | -50.1824817518 | 0.548 | 0.898 | 0.115 | 376917 | 0.42790348 | DE |
156 | -3.927 | -93.5 | 4.2 | 4.2 | 0.115 | 195118 | 0.65703906 | DE |
260 | -10.307 | -97.4196597353 | 10.58 | 11.16 | 0.115 | 167130 | 2.41274429 | DE |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.